Atea Pharmaceuticals, Inc. (AVIR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.83+0.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVIR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -87.9% |
| Our one-year growth estimate | diamond | -84.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
AVIR — earnings miss
Dated 2026-05-12
Results of Operations and Financial Condition. On May 12, 2026, Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026 and other matters described in the press release. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained in Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for…
Why it matters: These results are crucial for Atea's growth. Positive results could boost investor confidence.
Supportive ifTopline results show a big improvement in treatment outcomes. This is better than current therapies.
Worry ifResults show no improvement or worse outcomes. This is compared to current therapies.
Why it matters: Cash balance updates will indicate if Atea maintains its financial runway through 2027. A strong cash position supports ongoing trials.
Worry ifCash and investments are over $200 million. This shows a strong financial position.
Less concerning ifCash and investments drop below $150 million, raising concerns about funding future trials.
Why it matters: Topline results will show how well BEM/RZR works for HCV outside North America.
Supportive ifThe C-FORWARD trial shows a sustained virologic response (SVR) rate over 90%.
Worry ifTopline results show an SVR rate below 90%. This means weaker effectiveness.
Why it matters: If healthcare sector revenue growth speeds up, it may help Atea's performance. A stronger sector can lift weaker stocks.
Supportive ifHealthcare sector revenue growth rises above 12% year over year.
Worry ifHealthcare sector revenue growth stays below 10% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$189 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $430 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,333 loss on $10,000 · 33.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on the treatment gap will highlight the market potential for BEM/RZR. A growing gap suggests strong demand for new therapies.
Supportive ifReports show the annual number of untreated HCV patients increases beyond 75,000.
Worry ifReports indicate the treatment gap is closing, with fewer than 75,000 untreated patients.
Why it matters: Topline results will show if Atea's HCV treatment is effective. This could impact future sales and growth.
Supportive ifTopline results from the C-BEYOND trial show sustained virologic response (SVR12) above 95%.
Worry ifSVR12 is below 90%. This shows low effectiveness.
Why it matters: Results will show progress in creating a treatment for HEV. This is a big need.
Supportive ifPositive results from the AT-587 Phase 1 trial show safety and efficacy in weak patients.
Worry ifResults from the AT-587 Phase 1 trial show safety issues or lack of efficacy.
Why it matters: Another earnings miss may show problems with making money and investor trust.
Worry ifQ2 earnings report shows a loss greater than the previous quarter's -$48M.
Less concerning ifQ2 earnings report shows a narrower loss or a profit.
Why it matters: Starting the Phase 1 program for AT-587 could open a new revenue stream. It targets a serious unmet need.
Supportive ifAtea announces the start of the Phase 1 clinical program for AT-587.
Worry ifThe initiation of the Phase 1 program is delayed beyond mid-2026.
Why it matters: Completing enrollment is a key step for Atea's HCV program. It shows progress and commitment to the timeline.
Supportive ifC-FORWARD trial enrollment is completed by mid-2026 as planned.
Worry ifEnrollment is now delayed past mid-2026. This suggests possible problems.